Managing Vesicant Extravasations
Open Access
- 1 March 2008
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 13 (3), 284-288
- https://doi.org/10.1634/theoncologist.2007-0191
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe how vesicant chemotherapy drugs can extravasate from implanted ports.Recommend procedures to obtain a blood return from central venous access devices.Evaluate the signs and symptoms of a vesicant extravasation.Administer the FDA-approved vesicant extravasation treatments and antidotes. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com Extravasation is an unusual but potentially severe complication of vesicant chemotherapy administration. Some extravasation injuries prompt litigation and the oncologist's actions, or lack of action, are scrutinized in the courtroom. This article presents advice and recommendations for treating patients who receive vesicants and includes a discussion of FDA-approved vesicant extravasation treatments and antidotes.Keywords
This publication has 10 references indexed in Scilit:
- Extravasation ManagementSeminars in Oncology Nursing, 2007
- Totect™: A New Agent for Treating Anthracycline ExtravasationClinical Journal of Oncology Nursing, 2007
- Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studiesAnnals Of Oncology, 2006
- Extravasation of Chemotherapeutic Agents: Prevention and TreatmentSeminars in Oncology, 2006
- Extravasation of systemic hemato-oncological therapiesAnnals Of Oncology, 2004
- Intrathoracic Extravasation of Antineoplastic AgentsAmerican Journal of Clinical Oncology, 2003
- A review of clinical experience with paclitaxel extravasationsSupportive Care in Cancer, 2003
- Retrospective Study of the Management of Chemotherapeutic Extravasation InjuryAnnals of Plastic Surgery, 2002
- Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial—The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy TrialJournal of Vascular and Interventional Radiology, 2001
- Nursing Management of Adriamycin ExtravasationThe American Journal of Nursing, 1979